Table 1 Characteristics of patients who received Tenofovir, TTSH, Singapore, Jul. 2007 – Dec. 2009 (N = 226)
From: Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
No (%) of patients at TDF Initiation | |
|---|---|
Sex | |
Male | 203 (89.9) |
Female | 23 (10.1) |
Ethnicity | |
Chinese | 176 (78.6) |
Malay | 26 (11.6) |
Indian | 10 (4.5) |
Others | 12 (5.3) |
Age | |
Median (range) | 46 (23 – 82) |
Weight | |
Median (IQR) | 60.0 [53.75 - 68.0] |
ART Regimen | |
NNRTI-based | 118 (52.2) |
PI - based | 108 (47.8) |
Co-morbidity | |
Hepatitis B co-infection | 63 (27.9) |
Diabetes mellitus | 26 (11.5) |
Hypertension | 23 (10.2) |
Chronic renal disease | 2 (0.9) |
CD4 cell count (cells/mm 3 ) | |
Median [IQR] | 127 [38–258] |
Viral Load (Log 10 Copies/mL) | |
Median [IQR] | 4.9 [4.2-5.5] |
Creatinine clearance (mL/min) | |
Median [IQR] | 82.7 [71.4-101.7] |
>/= 90 | 72 (43.3) |
60-89 | 73 (43.9) |
30-59 | 20 (12.2) |
<30 | 1 (0.6) |